THESIS
2006
xv, 131 leaves : col. ill. ; 30 cm
Abstract
In this project, I used reverse immunology to identify the peptide HCA661
246-254 as the dominant epitope of HCA661, a newly identified CT antigen presented by HLA molecules in hepatocellular carcinoma (HCC) patients. HCA661
246-254 was able to generate peptide-specific T cells which recognized HCA66
+/HLA-A2
+ cancer cell line HepG2. Results of LDH cytotoxicity and ELISPOT assays confirmed that HCA661
246-254 was able to activate T cells specifically targeting HepG2 cells. Intracellular IFN-γ secretion assay further confirmed the targeting activity of HCA661
246-254-specific T cells. The results of this study indicate that HCA661
246-254 is the most frequently presented peptide by cancer cells on HLA-A2 molecules. HCA661
246-254 may be a good candidate for clinical analysis....[
Read more ]
In this project, I used reverse immunology to identify the peptide HCA661
246-254 as the dominant epitope of HCA661, a newly identified CT antigen presented by HLA molecules in hepatocellular carcinoma (HCC) patients. HCA661
246-254 was able to generate peptide-specific T cells which recognized HCA66
+/HLA-A2
+ cancer cell line HepG2. Results of LDH cytotoxicity and ELISPOT assays confirmed that HCA661
246-254 was able to activate T cells specifically targeting HepG2 cells. Intracellular IFN-γ secretion assay further confirmed the targeting activity of HCA661
246-254-specific T cells. The results of this study indicate that HCA661
246-254 is the most frequently presented peptide by cancer cells on HLA-A2 molecules. HCA661
246-254 may be a good candidate for clinical analysis.
Post a Comment